| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Impact BioMedical, Inc.$0.54
+0.01 (+1.09%)
Market Cap
-
EPS
-
P/E Ratio
-
Value Trade
28.02 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
67.37 K
52 Week Range
-
% held by Insiders
0.46 %
% held by Institutions
3.45 %
Enterprise Value
-
Total Shares
107.52 M
Short %
6.4 %
Float Shares
11.72 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IBO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Impact BioMedical, Inc. (IBO) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
IBO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IBO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IBO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IBO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
IBO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-IBO
Apr 3, 2026Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
Impact BioMedical Inc. reported a 'going concern' audit opinion in its 2025 10-K filing, indicating financial uncertainties. Despite this, the company is moving forward with plans to merge with Dr. Ashley's Ltd., expected to finalize by July 1, 2026. The announcement does not alter the financial statements for 2025.
Read more →-IBO
Jun 21, 2025Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on
Dr Ashleys Limited and Impact BioMedical Inc. have announced a strategic merger, aiming to enhance their combined market reach and accelerate the development of innovative pharmaceutical treatments. The transaction will involve Dr Ashleys acquiring Impact BioMedical through a reverse merger, resulting in a new entity traded on the NYSE American under the name 'Dr Ashleys Limited.' Both companies have received board approval for the merger, which will allow them to better capitalize on their respective strengths in research and development. The merger is subject to approval from Impact BioMedical's shareholders and regulatory authorities.
Read more →-IBO
Sep 16, 2024Impact BioMedical Inc. Announces Pricing of Initial Public Offering
Impact BioMedical Inc. has announced the pricing for its initial public offering (IPO), offering 1,500,000 shares at $3.00 per share. The shares are scheduled to start trading on the NYSE American under the ticker symbol 'IBO' on September 16, 2024. Additionally, the company has provided the underwriters a 45-day option to purchase 225,000 additional shares at the same price. The IPO is expected to close on September 17, 2024, pending customary closing conditions.
Read more →Competitive Position
How IBO ranks across every disease it competes inCompetitive Position is a premium feature
See how IBO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial